Monitoring Ovarian Carcinoma With CA 125, CA 19–9, CA 15–3 and CEA in Serum, Ascites and Tumor Tissue

Journal of Cancer Research and Clinical Oncology - Germany
doi 10.1007/bf02580306
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

CA 19-9 and CA 125 Determination by Immunoluminometric Assay

Clinical Chemistry and Laboratory Medicine
BiochemistryMedicineClinical Biochemistry
1990English

CA 72-4 Compared With Cea and CA 19-9 as a Marker of Some Gastrointestinal Malignancies

International Journal of Biological Markers
OncologyCancer ResearchClinical BiochemistryForensic MedicineMedicinePathology
1999English

Serum McA, CA 125 and CA 19.9 Determination in Primary Breast Cancer

Biochemical Society Transactions
Biochemistry
1996English

Elevated Serum CA 19-9 Levels in Dermoid Cyst: A Predictor of Ovarian Torsion and Tissue Necrosis?

International Journal of Reproduction, Contraception, Obstetrics and Gynecology
2019English

Tumor Markers CA 125 and CA 19–9 in Cord Blood and During Infancy: Developmental Changes and Use in Pediatric Germ Cell Tumors

Pediatric Research
Child HealthPediatricsPerinatology
1995English

Prognostic Value of Monitoring Tumour Markers CA 15-3 and CEA During Fulvestrant Treatment

BMC Cancer
Cancer ResearchOncologyGenetics
2006English

Increased Serum CA 19-9 Antibodies in Sjogren's Syndrome.

Postgraduate Medical Journal
Medicine
1998English

Clinical Evaluation of Tumor Markers CA 19-9 and CA 125 in Diseases of the Digestive System: Diagnostic Usefulness Especially in Carcinoma of the Pancreas and Biliary Tract.

Japanese Journal of Gastroenterological Surgery
SurgeryGastroenterology
1985English

Tumour-Associated Trypsin Inhibitor (TATI) in Human Ovarian Cyst Fluid. Comparison With CA 125 and CEA

British Journal of Cancer
Cancer ResearchOncology
1987English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy